AGL 5.76 Decreased By ▼ -0.07 (-1.2%)
ANL 9.03 No Change ▼ 0.00 (0%)
AVN 79.16 Increased By ▲ 0.36 (0.46%)
BOP 5.21 Increased By ▲ 0.05 (0.97%)
CNERGY 4.73 Increased By ▲ 0.05 (1.07%)
EFERT 81.25 Increased By ▲ 0.70 (0.87%)
EPCL 50.99 Decreased By ▼ -0.72 (-1.39%)
FCCL 13.53 Decreased By ▼ -0.08 (-0.59%)
FFL 5.82 Decreased By ▼ -0.03 (-0.51%)
FLYNG 7.29 Increased By ▲ 0.17 (2.39%)
FNEL 4.81 Decreased By ▼ -0.04 (-0.82%)
GGGL 8.88 Decreased By ▼ -0.02 (-0.22%)
GGL 15.83 Decreased By ▼ -0.22 (-1.37%)
HUMNL 5.90 Increased By ▲ 0.10 (1.72%)
KEL 2.60 No Change ▼ 0.00 (0%)
LOTCHEM 30.03 Increased By ▲ 0.02 (0.07%)
MLCF 25.34 Decreased By ▼ -0.06 (-0.24%)
OGDC 72.65 Increased By ▲ 0.50 (0.69%)
PAEL 15.40 Decreased By ▼ -0.09 (-0.58%)
PIBTL 5.11 Increased By ▲ 0.10 (2%)
PRL 16.50 Increased By ▲ 0.10 (0.61%)
SILK 1.08 Decreased By ▼ -0.02 (-1.82%)
TELE 9.60 Decreased By ▼ -0.05 (-0.52%)
TPL 7.41 Increased By ▲ 0.11 (1.51%)
TPLP 19.35 Increased By ▲ 0.12 (0.62%)
TREET 21.92 Decreased By ▼ -0.03 (-0.14%)
TRG 144.85 Decreased By ▼ -0.12 (-0.08%)
UNITY 17.53 Increased By ▲ 0.91 (5.48%)
WAVES 10.00 No Change ▼ 0.00 (0%)
WTL 1.38 Increased By ▲ 0.01 (0.73%)
BR100 4,268 Increased By 38.3 (0.9%)
BR30 15,882 Increased By 59.8 (0.38%)
KSE100 42,414 Increased By 342.5 (0.81%)
KSE30 15,689 Increased By 184.1 (1.19%)
Follow us

Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.

"We're very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up," Dean Li, president of Merck Research Laboratories, said at J.P. Morgan's annual healthcare conference.

Data on molnupiravir's impact against Omicron is not yet available, but the pill was shown to be 30% effective at reducing hospitalizations and deaths, based on data from 1,433 patients, as per latest data released in November.

India says safety concerns restricting use of Merck COVID pill

However, this data showed significantly less effectiveness as compared to the previous figure of 50%.

The pill had received authorization from the US Food and Drug Administration last month, as well as in several other countries like the UK, Japan and India, with various countries including US signing agreements to buy the drug.

Comments

Comments are closed.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

Pakistan receives $500mn from AIIB: finance ministry

PD prepares $496m gas pipeline augmentation plan

Intra-day update: rupee registers marginal losses against US dollar

Hina Rabbani Khar meets interim Afghan government leadership on one-day Kabul trip

Oil jumps on hopes for easing in China’s COVID controls

Islamabad court extends Azam Swati’s remand for 4 days

S&P Global lowers 2023 growth forecast for emerging markets

IMF, govt begin virtual engagement

Dar willing to allow sugar export?

Tax-exempted areas: FBR sets up checkposts to monitor supplies